Production (Stage)
XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -670.37% | 120.87% | -445.09% | 105.63% | -211.84% |
| Total Depreciation and Amortization | -0.38% | 0.77% | -21.52% | 2.80% | 31.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.80% | -208.24% | 84.52% | -179.55% | 155.68% |
| Change in Net Operating Assets | 198.05% | -580.07% | -91.40% | 301.65% | 20.69% |
| Cash from Operations | 27.38% | -17.89% | -2.09% | 43.52% | -0.45% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.00% | 82.76% | -154.95% | -250.00% | 73.47% |
| Cash from Investing | 15.00% | 82.76% | -154.95% | -250.00% | 73.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.76% | -2.25% | -149.44% | 44.03% | 6.47% |
| Issuance of Common Stock | -92.43% | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.84% | -- | -- | 100.00% | -0.78% |
| Cash from Financing | -93.89% | 5,086.49% | -149.44% | -100.52% | 645.50% |
| Foreign Exchange rate Adjustments | 102.52% | -324.10% | 880.00% | 73.12% | -520.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -434.53% | 122.23% | -2.73% | -295.20% | 123.91% |